Tranilast
Alternative Names: MK 341; NU3450; Rizaben; SB 252218Latest Information Update: 25 Nov 2021
At a glance
- Originator Kissei Pharmaceutical
- Developer Kissei Pharmaceutical; Nuon Therapeutics
- Class Anthranilic acids; Antiallergics; Antiasthmatics; Ischaemic heart disorder therapies; Small molecules
- Mechanism of Action Collagen inhibitors; Immunomodulators; Mast cell stabilisers; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-myc modulators; SLC2A9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Allergic conjunctivitis; Allergic rhinitis; Asthma; Atopic dermatitis; Hypertrophic scars; Keloids
- Discontinued Cancer metastases; Coronary artery restenosis; Hyperuricaemia; Multiple sclerosis; Rheumatoid arthritis; Vascular restenosis
Most Recent Events
- 31 Dec 2010 Nuon Therapeutics completes a phase II trial in Rheumatoid arthritis in USA, Argentina, Bulgaria, Czech Republic, Germany, Mexico, Serbia & United Kingdom
- 28 May 2010 Tranilast is still in phase II trials for Rheumatoid arthritis worldwide except Japan and South Korea (http://www.kissei.co.jp/e_contents/relation/pipeline.html)
- 24 Jul 2007 Kissei Pharmaceutical and Nuon Therapeutics enter into a licensing, supply and collaboration agreement for tranilast